The Fever-Tree share price has doubled. Is it time to buy the stock?

The Fever-Tree share price has doubled since late March. But the stock now looks expensive, says Roland Head. Should you keep buying?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Back in April, I noted that top fund manager Nick Train — often known as Britain’s Warren Buffett — had been buying posh mixers firm Fevertree Drinks (LSE: FEVR). Fever-Tree’s share price has now doubled from the lows seen in late March. Is it too late to buy the shares?

In this piece, I’m going to catch up on the latest news from the company and explain why I think this impressive business could continue to grow.

Trading well in tough conditions

Fever-Tree’s share price fell by around 5% after last week’s half-year trading update. I think that’s a fair reaction. The company’s sales have been hit hard by pub, bar, and restaurant closures all over the world.

In the UK, these so-called on-trade sales accounted for half the group’s total sales last year. On-trade sales obviously fell to zero during lockdown. Fortunately, stay-at-home drinkers increased their purchases by 34%. This made up for much of the shortfall.

The company reported similar patterns in its European and US markets, with particularly strong growth in the US off-trade market.

However, I was a little disappointed the company didn’t give a clear indication of how its total sales changed during the first half of the year. We’ll have to wait for the half-year results in September for that information.

Can the Fever-Tree share price keep climbing?

The big question is how we should value this stock. Historically, Fever-Tree’s policy of outsourcing manufacturing has made it a very profitable business. The group’s operating profit margin was about 28% last year.

Growth has been very strong historically too. However, things are getting more difficult. Fever-Tree’s profits will obviously fall this year due to Covid-10. But profits also fell in 2019, which I view as a sign that UK growth has probably hit a natural limit.

The big question is whether the company can succeed in the USA in the way it has done in the UK. One problem is that Americans don’t drink as much G&Ts as us Britons. The other possibility is the craft gin boom has already peaked and entered a more mature phase.

Wait and see

My view is that Fever-Tree’s success in the US will depend on newer products, such as ginger ale and cola. Due to the impact of Covid-19, I think we’ll have to wait until next year before we can get an accurate idea of how well these products are selling in the US.

In the meantime, Fever-Tree’s share price of around 2,300p means the stock is trading on 45x 2021 forecast profits. A lot of success is already priced into the shares. Although I think this business probably will continue to grow, I’m not sure it justifies such a high valuation.

If I was a shareholder, I’d sit tight for now and plan to buy more during the next market correction.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 no-brainer buys for my Stocks and Shares ISA in 2025

Harvey Jones picks out a couple of thriving FTSE 100 companies that he's keen to add to his Stocks and…

Read more »

Number three written on white chat bubble on blue background
Investing For Beginners

3 investing mistakes to avoid when buying UK shares for 2025

Jon Smith flags up several points for investors to note when it comes to thinking about which UK shares to…

Read more »

Investing Articles

Will the rocketing Scottish Mortgage share price crash back to earth in 2025?

The recent surge in the Scottish Mortgage share price caught Harvey Jones by surprise. He was on the brink of…

Read more »

Investing Articles

2 cheap shares I’ll consider buying for my ISA in 2025

Harvey Jones will be on the hunt for cheap shares for his ISA in 2025 and these two unsung FTSE…

Read more »

Investing Articles

I am backing the Glencore share price — at a 3-year low — to bounce back in 2025

The Glencore share price has been falling for some time, but Andrew Mackie argues demand for metals will reverse that…

Read more »

Road trip. Father and son travelling together by car
Investing Articles

A 10% dividend yield? There could be significant potential here to earn a second income

Mark Hartley delves into the finances and performance of one of the top-earning dividend stocks in his second income portfolio.

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

Charlie Munger recommended shares in this growth company back in 2022. Here’s what’s happened since

One of Charlie Munger’s key insights is that a high P/E ratio shouldn’t put investors off buying shares if the…

Read more »

Investing Articles

What might 2025 have in store for the Aviva share price? Let’s ask the experts

After a rocky five years, the Aviva share price has inched up in 2024. And City forecasters reckon we could…

Read more »